Company overview
Broken String Biosciences offers the INDUCE-seq® platform for unbiased, genome-wide detection of on- and off-target DNA double-strand breaks in gene editing therapies. This PCR-free, cell-based technology enables precise safety assessments in days, supporting cell and gene therapy developers from discovery to commercialization. They provide lab services, in-house kits via the Catalyst Early Access Program, and bioinformatics analysis for actionable insights.
Broken String is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include gene editing safety, induce-seq, off-target detection, crispr analysis, cell gene therapy.
Structured facts
- Website
- https://www.brokenstringbio.com
- Markets served
- United States & Americas
- Keywords
- gene editing safety, induce-seq, off-target detection, crispr analysis, cell gene therapy
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What is INDUCE-seq® and how does it work?
- INDUCE-seq® is a scalable, PCR-free platform that directly labels and captures DNA breaks in cells using next-generation sequencing, enabling genome-wide detection of on- and off-target edits from any nuclease-based system in days.
- What products and services are available for gene editing safety?
- Products include BreakMap™ with cloud-based bioinformatics and reporting; services encompass lab-based analysis and the Catalyst Early Access Program for in-house use of INDUCE-seq® kits in clinically relevant cells.
- What are the key capabilities and regulatory benefits?
- The platform is cell- and nuclease-agnostic, measures editing kinetics and repair pathways, supports patient-specific genotypes, and addresses regulatory scrutiny by providing precise, quantitative safety data early in development.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
